395639-03-9

Basic information

• Product Name: N,N-DI-BOC-4-NITROANILINE
• Synonyms: N,N-DI-BOC-4-NITROANILINE
• CAS NO: 395639-03-9
• Molecular Formula: C16H22N2O6
• Molecular Weight: 338.36
• Mol File: 395639-03-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N,N-DI-BOC-4-NITROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-DI-BOC-4-NITROANILINE(395639-03-9)
• EPA Substance Registry System: N,N-DI-BOC-4-NITROANILINE(395639-03-9)

Safety Data

• Hazardous Substances Data: 395639-03-9(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 1083049-80-2 C₁₇H₁₉ClN₄O₃S 
• 1082936-67-1 C₁₉H₁₉ClN₄O₃S 
• 1082936-73-9 C₂₀H₂₁ClN₄O₃S 
• 1082936-75-1 C₂₁H₂₁ClN₄O₃S 
• 1082936-94-4 C₂₃H₂₀ClN₅O₃S 

Relevant articles and documents

Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core

This Letter describes the lead optimization of the VU0486321 series of mGlu1 positive allosteric modulators (PAMs). While first generation PAMs from Roche were reported in the late 1990s, little effort has focused on the development of mGlu1 PAMs since. New genetic data linking loss-of-function mutant mGlu1 receptors to schizophrenia, bipolar disorder and other neuropsychiatric disorders has rekindled interest in the target, but the ideal in vivo probe, for example, with good PK, brain penetration and low plasma protein binding, for robust target validation has been lacking. Here we describe the first modifications to the central aryl core of the VU0486321 series, where robust SAR was noted. Moreover, structural variants were identified that imparted selectivity (up to >793-fold) versus mGlu4.

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

Selective nitrolytic deprotection of N-BOC-amines and N-BOC-amino acids derivatives

The extension of the deprotection procedure using HNO3 in CH2Cl2 to a number of appropriately selected N-BOC-masked amines and derivatives of natural amino acids was investigated. The method was found to work effectively with almost all tested substrates, with the exception of activated aromatic amines and heterocycles which underwent unavoidable faster oxidation. Alanine, phenylalanine, serine and lysine derivatives were efficiently deprotected, as well as dipeptide Ala-Phe, preserving the configuration of the substrates and without affecting copresent Z and ester functions, with a remarkable selectivity towards acid sensitive t-butyl esters. The obtained amino acids esters, isolated and characterized in the form of nitrates salts, proved to be suitable intermediates to be used in peptide synthesis.